Active, not recruitingPhase 2NCT03872427
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Studying Malignant peripheral nerve sheath tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Funda Meric-BernstamUniversity of Texas MD Anderson Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 54 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2023
Study locations (20)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
- Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Clinical Research Center, Fairway, Kansas, United States
- HaysMed, Hays, Kansas, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03872427 on ClinicalTrials.govOther trials for Malignant peripheral nerve sheath tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06693284A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]University of Minnesota
- RECRUITINGPHASE2NCT04872543A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT04222413Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT03141021Multi-Institutional Registry for Malignant Peripheral Nerve Sheath TumorsWashington University School of Medicine
See all trials for Malignant peripheral nerve sheath tumor →